{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:58:16Z","timestamp":1769630296704,"version":"3.49.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2021-0554_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the diagnostic performance of the prostate health index (PHI) and of the percentage of [-2]proPSA (%[-2]proPSA) calculated with total and free PSA from non-Beckman Coulter manufacturers (Roche and Abbott), and compare it with the fully Beckman Coulter [-2]proPSA derivatives.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-0554_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, 237 men (PSA: 2\u201310\u00a0\u03bcg\/L) scheduled for prostate biopsy were enrolled. %[-2]proPSA and PHI were calculated with total and free PSA from three manufacturers. Beckman Coulter PSA and [-2]proPSA were performed on the Access 2 analyzer (Hybritech calibration). Roche PSA was performed on the cobas e411 and the Abbott PSA on the Architect i2000sr. Statistical analysis was performed, considering prostate cancer (PCa) as the outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-0554_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Univariate analysis showed that all indices were predictors of cancer, irrespective of the manufacturer (p&lt;0.001). The AUC was similar for all manufacturers, both for %[-2]proPSA (Beckman Coulter: 0.756; Roche: 0.770; Abbott: 0.756) and PHI (Beckman Coulter: 0.776; Roche: 0.785; Abbott: 0.778). When considering the cutoffs that allowed 90% sensitivity, [-2]proPSA derivatives calculated with Roche and Abbott PSA had similar specificities and predictive values when compared to Beckman Coulter. The percentage of missed cancers (8\u20139%) was the same between manufacturers. The percentage of spared biopsies was significantly higher with Roche\u2019s PHI (21.0%) and Abbott\u2019s PHI (20.6%) than with Beckman Coulter\u2019s PHI (17.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-0554_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the PSA range between 2 and 10\u00a0\u03bcg\/L, [-2]proPSA derivatives maintain their diagnostic performance in PCa detection when calculated with PSA from Roche and Abbott. This can lead to a broader implementation of these indices in clinical laboratories worldwide.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2021-0554","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T02:14:10Z","timestamp":1627438450000},"page":"1869-1877","source":"Crossref","is-referenced-by-count":4,"title":["The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers"],"prefix":"10.1515","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-4094","authenticated-orcid":false,"given":"Manuel M.","family":"Garrido","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology , Centro Hospitalar Universit\u00e1rio de Lisboa Central , Lisbon , Portugal"},{"name":"Department of Laboratory Medicine, Faculdade de Medicina da Universidade de Lisboa , Lisbon , Portugal"}]},{"given":"Ruy","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Biomathematics Laboratory , Faculdade de Medicina da Universidade de Lisboa , Lisbon , Portugal"}]},{"given":"Lu\u00eds C.","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Department of Urology , Centro Hospitalar Universit\u00e1rio de Lisboa Central , Lisbon , Portugal"},{"name":"Department of Urology , Faculdade de Ci\u00eancias M\u00e9dicas da Universidade Nova de Lisboa , Lisbon , Portugal"}]},{"given":"Stefan","family":"Holdenrieder","sequence":"additional","affiliation":[{"name":"Institute of Laboratory Medicine, Munich Biomarker Research Center , Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen , Munich , Germany"}]},{"given":"Jo\u00e3o T.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology , Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o , Porto , Portugal"},{"name":"Department of Biomedicine , Faculdade de Medicina da Universidade do Porto , Porto , Portugal"},{"name":"EPIUnit, Instituto de Sa\u00fade P\u00fablica , Universidade do Porto , Porto , Portugal"}]}],"member":"374","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"2023033111304608408_j_cclm-2021-0554_ref_001","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Miller, KD, Fuchs, HE, Jemal, A. Cancer Statistics, 2021. Ca Cancer J Clin 2021;71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","DOI":"10.3322\/caac.21654"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_002","doi-asserted-by":"crossref","unstructured":"Arnold, M, Karim-Kos, HE, Coebergh, JW, Byrnes, G, Antilla, A, Ferlay, J, et al.. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Canc 2015;51:1164\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2013.09.002.","DOI":"10.1016\/j.ejca.2013.09.002"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_003","doi-asserted-by":"crossref","unstructured":"Kim, EH, Andriole, GL. Prostate-specific antigen-based screening: controversy and guidelines. BMC Med 2015;13:1\u20134. https:\/\/doi.org\/10.1186\/s12916-015-0296-5.","DOI":"10.1186\/s12916-015-0296-5"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_004","doi-asserted-by":"crossref","unstructured":"Wolf, AM, Wender, RC, Etzioni, RB, Thompson, IM, Amico, AV, Volk, RJ, et al.. American Cancer Society Guideline for the early detection of prostate cancer update 2010. Canc J 2010;60:70\u201398. https:\/\/doi.org\/10.3322\/caac.20066.","DOI":"10.3322\/caac.20066"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_005","doi-asserted-by":"crossref","unstructured":"Filella, X, Gim\u00e9nez, N. Evaluation of [- 2] proPSA and prostate health index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729\u201339. https:\/\/doi.org\/10.1515\/cclm-2012-0410.","DOI":"10.1515\/cclm-2012-0410"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_006","doi-asserted-by":"crossref","unstructured":"Loeb, S, Bjurlin, MA, Nicholson, J, Tammela, TL, Penson, DF, Carter, HB, et al.. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046\u201355. https:\/\/doi.org\/10.1016\/j.eururo.2013.12.062.","DOI":"10.1016\/j.eururo.2013.12.062"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_007","doi-asserted-by":"crossref","unstructured":"Mikolajczyk, SD, Marks, LS, Partin, AW, Rittenhouse, HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59:797\u2013802. https:\/\/doi.org\/10.1016\/s0090-4295(01)01605-3.","DOI":"10.1016\/S0090-4295(01)01605-3"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_008","doi-asserted-by":"crossref","unstructured":"Catalona, WJ, Partin, AW, Sanda, MG, Wei, JT, Klee, GG, Bangma, CH, et al.. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0\u00a0ng\/ml prostate specific antigen range. J Urol 2011;185:1650\u20135. https:\/\/doi.org\/10.1016\/j.juro.2010.12.032.","DOI":"10.1016\/j.juro.2010.12.032"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_009","doi-asserted-by":"crossref","unstructured":"Liang, Y, Ankerst, DP, Ketchum, NS, Ercole, B, Shah, G, Shaughnessy, JD, et al.. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol 2011;185:104\u201310. https:\/\/doi.org\/10.1016\/j.juro.2010.08.088.","DOI":"10.1016\/j.juro.2010.08.088"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_010","doi-asserted-by":"crossref","unstructured":"Le, BV, Griffin, CR, Loeb, S, Carvalhal, GF, Kan, D, Baumann, NA, et al.. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010;183:1355\u20139. https:\/\/doi.org\/10.1016\/j.juro.2009.12.056.","DOI":"10.1016\/j.juro.2009.12.056"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_011","doi-asserted-by":"crossref","unstructured":"Lazzeri, M, Haese, A, Abrate, A, De La Taille, A, Redorta, JP, McNicholas, T, et al.. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS. BJU Int 2013;112:313\u201321. https:\/\/doi.org\/10.1111\/bju.12217.","DOI":"10.1111\/bju.12217"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_012","doi-asserted-by":"crossref","unstructured":"Jansen, FH, van Schaik, RHN, Kurstjens, J, Horninger, W, Klocker, H, Bektic, J, et al.. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2010.02.003.","DOI":"10.1016\/j.eururo.2010.02.003"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_013","doi-asserted-by":"crossref","unstructured":"Ferro, M, Bruzzese, D, Perdon\u00e0, S, Marino, A, Mazzarella, C, Perruolo, G, et al.. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng\/ml. PloS One 2013;8:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0067687.","DOI":"10.1371\/journal.pone.0067687"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_014","doi-asserted-by":"crossref","unstructured":"Guazzoni, G, Nava, L, Lazzeri, M, Scattoni, V, Lughezzani, G, MacCagnano, C, et al.. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10\u00a0ng\/ml: results of a prospective study in a clinical setting. Eur Urol 2011;60:214\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2011.03.052.","DOI":"10.1016\/j.eururo.2011.03.052"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_015","unstructured":"European Association of Urology. EAU guidelines: prostate cancer. Uroweb [Internet]. Available from: https:\/\/uroweb.org\/guideline\/prostate-cancer\/#5 [Accessed 23 Aug 2020]."},{"key":"2023033111304608408_j_cclm-2021-0554_ref_016","doi-asserted-by":"crossref","unstructured":"Carter, HB, Albertsen, PC, Barry, MJ, Etzioni, R, Freedland, SJ, Greene, KL, et al.. Early detection of prostate cancer: AUA guideline. J Urol 2013;190:419\u201326. https:\/\/doi.org\/10.1016\/j.juro.2013.04.119.","DOI":"10.1016\/j.juro.2013.04.119"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_017","doi-asserted-by":"crossref","unstructured":"Epstein, JI, Egevad, L, Amin, MB, Delahunt, B, Srigley, JR, Humphrey, PA. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244\u201352. https:\/\/doi.org\/10.1097\/pas.0000000000000530.","DOI":"10.1097\/PAS.0000000000000530"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_018","doi-asserted-by":"crossref","unstructured":"Bul, M, Zhu, X, Valdagni, R, Pickles, T, Kakehi, Y, Rannikko, A, et al.. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597\u2013603. https:\/\/doi.org\/10.1016\/j.eururo.2012.11.005.","DOI":"10.1016\/j.eururo.2012.11.005"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_019","doi-asserted-by":"crossref","unstructured":"Bokhorst, LP, Valdagni, R, Rannikko, A, Kakehi, Y, Pickles, T, Bangma, CH, et al.. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 2016;70:954\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.007.","DOI":"10.1016\/j.eururo.2016.06.007"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_020","doi-asserted-by":"crossref","unstructured":"Semjonow, A, K\u00f6pke, T, Eltze, E, Pepping-Schefers, B, B\u00fcrgel, H, Darte, C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010;43:926\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.04.062.","DOI":"10.1016\/j.clinbiochem.2010.04.062"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_021","doi-asserted-by":"crossref","unstructured":"Stamey, TA. Second stanford conference on international standardization of prostate-specific antigen immunoassays: september 1 and 2, 1994. Urology 1995;45:173\u201384. https:\/\/doi.org\/10.1016\/0090-4295(95)80001-8.","DOI":"10.1016\/0090-4295(95)80001-8"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_022","doi-asserted-by":"crossref","unstructured":"Stephan, C, Bangma, C, Vignati, G, Bartsch, G, Lein, M, Jung, K, et al.. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials\u00a0\u2013 analysis of 1098 patients in four centers. Int J Biol Markers 2009;24:65\u20139. https:\/\/doi.org\/10.5301\/jbm.2009.1349.","DOI":"10.5301\/JBM.2009.1349"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_023","doi-asserted-by":"crossref","unstructured":"Fill\u00e9e, C, Tombal, B, Philippe, M. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access\u00ae prostate-specific antigen assays. Clin Chem Lab Med 2010;48:285\u20138. https:\/\/doi.org\/10.1515\/CCLM.2010.039.","DOI":"10.1515\/CCLM.2010.039"},{"key":"2023033111304608408_j_cclm-2021-0554_ref_024","unstructured":"American Urological Association. Prostate cancer: early detection guideline - American Urological Association. [Internet]. Available from: https:\/\/www.auanet.org\/guidelines\/prostate-cancer-early-detection-guideline [Accessed 23 Aug 2020]."},{"key":"2023033111304608408_j_cclm-2021-0554_ref_025","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: prostate cancer early detection.Version 2.2020 [Internet]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf [Accessed 26 Oct 2020]."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-0554\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-0554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T15:12:26Z","timestamp":1680275546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-0554\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,14]]},"published-print":{"date-parts":[[2021,10,26]]}},"alternative-id":["10.1515\/cclm-2021-0554"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2021-0554","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]}}}